Publications

Detailed Information

INTENSITY-MODULATED RADIATION THERAPY WITH SIMULTANEOUS INTEGRATED BOOST TECHNIQUE FOLLOWING NEOADJUVANT CHEMOTHERAPY FOR LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA

DC Field Value Language
dc.contributor.authorKim, Kyubo-
dc.contributor.authorWu, Hong-Gyun-
dc.contributor.authorKim, Hak Jae-
dc.contributor.authorSung, Myung-Whun-
dc.contributor.authorLee, Se-Hoon-
dc.contributor.authorKim, Hee Jung-
dc.contributor.authorPark, Charn Il-
dc.contributor.authorHeo, Dae Seog-
dc.contributor.authorKim, Kwang Hyun-
dc.date.accessioned2012-05-24T02:25:27Z-
dc.date.available2012-05-24T02:25:27Z-
dc.date.issued2009-09-
dc.identifier.citationHEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK; Vol.31 9; 1121-1128ko_KR
dc.identifier.issn1043-3074-
dc.identifier.urihttps://hdl.handle.net/10371/76387-
dc.description.abstractBackground. Our aim was to evaluate the feasibility and efficacy of intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal cancer (NPC). Methods. Between April 2004 and December 2006, 25 patients with stage IIB to IVB NPC underwent 3 cycles of neoadjuvant chemotherapy followed by IMRT using SIB technique. Neoadjuvant chemotherapeutic regimens were 5-fluorouracil and cisplatin in 11 patients; docetaxel, 5-fluorouracil, and cisplatin in 8; and paclitaxel and cisplatin in 6. Dose prescription of IMRT was as follows: 67.5 Gy at 2.25 Gy/fraction to postchemotherapy gross tumor, 54 to 60 Gy at 1.8 to 2 Gy/fraction to subclinical disease, and 48 Gy at 1.6 Gy/fraction to elective neck. Seventeen patients received weekly cisplatin during the course of radiation therapy as well. Results. With a median follow-up of 29 months for survivors (range, 14-39), the 3-year local progression-free, regional progression-free, and distant metastasis-free survival rates were 89.6%, 87.2%, and 80.4%, respectively. Treatment was well tolerated despite the grade 3 mucositis (16%) and/or pharyngitis (16%). With follow-up, the frequency of xerostomia decreased. At 3 months after IMRT, the proportions of Radiation Therapy Oncology Group grades 0, 1, and 2 xerostomia were 13%, 38%, and 50%, respectively. At 24 months, the corresponding figures were 36%, 46%, and 18%, respectively. Conclusion. IMRT with SIB technique for locoregionally advanced NPC was feasible and effective regarding locoregional control and development of xerostomia, even after neoadjuvant chemotherapy. Definition of gross tumor volume by postchemotherapy extent of disease was also feasible. 2009 Wiley Periodicals, Inc. Head Neck 31: 1121-1128, 2009ko_KR
dc.language.isoenko_KR
dc.publisherJOHN WILEY & SONS INCko_KR
dc.subjectnasopharyngeal cancerko_KR
dc.subjectintensity-modulated radiation therapyko_KR
dc.subjectxerostomiako_KR
dc.subjectneoadjuvant chemotherapyko_KR
dc.subjectsimultaneous integrated boostko_KR
dc.titleINTENSITY-MODULATED RADIATION THERAPY WITH SIMULTANEOUS INTEGRATED BOOST TECHNIQUE FOLLOWING NEOADJUVANT CHEMOTHERAPY FOR LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMAko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김규보-
dc.contributor.AlternativeAuthor우홍균-
dc.contributor.AlternativeAuthor김학재-
dc.contributor.AlternativeAuthor성명훈-
dc.contributor.AlternativeAuthor김광현-
dc.contributor.AlternativeAuthor이세훈-
dc.contributor.AlternativeAuthor허대석-
dc.contributor.AlternativeAuthor김희중-
dc.contributor.AlternativeAuthor박찬일-
dc.identifier.doi10.1002/hed.21076-
dc.citation.journaltitleHEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK-
dc.description.citedreferenceLee NY, 2007, INT J RADIAT ONCOL, V69, pS13-
dc.description.citedreferenceYau TK, 2006, INT J RADIAT ONCOL, V66, P1004, DOI 10.1016/j.ijrobp.2006.06.106-
dc.description.citedreferenceLee SW, 2006, INT J RADIAT ONCOL, V65, P152, DOI 10.1016/j.ijrobp.2005.10.040-
dc.description.citedreferenceKwong DLW, 2006, INT J RADIAT ONCOL, V64, P374, DOI 10.1016/j.ijrobp.2005.07.968-
dc.description.citedreferenceWolden SL, 2006, INT J RADIAT ONCOL, V64, P57, DOI 10.1016/j.ijrobp.2005.03.057-
dc.description.citedreferenceBaujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037-
dc.description.citedreferenceWu SX, 2006, INT J RADIAT ONCOL, V66, pS40, DOI 10.1016/j.ijrobp.2005.12.041-
dc.description.citedreferenceAl-Amro A, 2005, INT J RADIAT ONCOL, V62, P508, DOI 10.1016/j.ijrobp.2004.09.050-
dc.description.citedreferenceLEE N, 2005, PRACTICAL ESSENTIALS, P135-
dc.description.citedreferenceLangendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074-
dc.description.citedreferenceChan ATC, 2004, J CLIN ONCOL, V22, P3053, DOI 10.1200/JCO.2004.05.178-
dc.description.citedreferenceJohnson FM, 2004, CANCER, V100, P991, DOI 10.1002/cncr.20079-
dc.description.citedreferenceLee N, 2002, INT J RADIAT ONCOL, V53, P12-
dc.description.citedreference*AJCC, 2002, AJCC CANC STAG MAN-
dc.description.citedreferenceMa J, 2001, J CLIN ONCOL, V19, P1350-
dc.description.citedreferenceMohan R, 2000, INT J RADIAT ONCOL, V46, P619-
dc.description.citedreferenceHong SM, 1999, INT J RADIAT ONCOL, V45, P901-
dc.description.citedreferenceChua DTT, 1998, CANCER, V83, P2270-
dc.description.citedreferenceCHAN ATC, 1995, INT J RADIAT ONCOL, V33, P569-
dc.description.citedreferenceCOX JD, 1995, INT J RADIAT ONCOL, V31, P1341-
dc.description.citedreferenceMARKS JE, 1982, CANCER, V50, P1042-
dc.description.citedreferenceKAPLAN EL, 1958, JAMA-J AM MED ASSOC, V457, P481-
dc.description.citedreferenceCOMMONTERMINOLOGY CR-
dc.description.tc11-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share